[go: up one dir, main page]

CY1111295T1 - Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2 - Google Patents

Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2

Info

Publication number
CY1111295T1
CY1111295T1 CY20111100113T CY111100113T CY1111295T1 CY 1111295 T1 CY1111295 T1 CY 1111295T1 CY 20111100113 T CY20111100113 T CY 20111100113T CY 111100113 T CY111100113 T CY 111100113T CY 1111295 T1 CY1111295 T1 CY 1111295T1
Authority
CY
Cyprus
Prior art keywords
crth2
treatment
diseases caused
pyrimidine derivatives
derivatives useful
Prior art date
Application number
CY20111100113T
Other languages
English (en)
Inventor
Tai-Wei Ly
Yuji Koriyama
Takashi Yoshino
Hiroki Sato
Kazuho Tanaka
Hiromi Sugimoto
Yoshihisa Manabe
Kevin Bacon
Klaus Urbahns
Masanori Seki
Takuya Shintani
Original Assignee
Actimis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals, Inc. filed Critical Actimis Pharmaceuticals, Inc.
Publication of CY1111295T1 publication Critical patent/CY1111295T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά παράγωγο πυριμιδίνης του τύπου (I)
CY20111100113T 2003-04-25 2011-02-03 Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2 CY1111295T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03009384A EP1471057B1 (en) 2003-04-25 2003-04-25 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
EP04727274A EP1633726B1 (en) 2003-04-25 2004-04-14 Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Publications (1)

Publication Number Publication Date
CY1111295T1 true CY1111295T1 (el) 2015-08-05

Family

ID=32946880

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100113T CY1111295T1 (el) 2003-04-25 2011-02-03 Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2

Country Status (33)

Country Link
US (2) US7812160B2 (el)
EP (2) EP1471057B1 (el)
JP (2) JP4671955B2 (el)
KR (1) KR101110491B1 (el)
CN (2) CN1809539B (el)
AR (1) AR043885A1 (el)
AT (2) ATE316077T1 (el)
AU (1) AU2004233966B2 (el)
BR (1) BRPI0409733A (el)
CA (1) CA2523439C (el)
CL (1) CL43596B (el)
CY (1) CY1111295T1 (el)
DE (2) DE60303238T2 (el)
DK (2) DK1471057T3 (el)
DO (1) DOP2004000875A (el)
ES (2) ES2257616T3 (el)
GT (1) GT200400079A (el)
HK (1) HK1095320A1 (el)
HN (1) HN2004000129A (el)
IL (1) IL171566A (el)
MX (1) MXPA05011399A (el)
MY (1) MY147984A (el)
NO (1) NO20055588L (el)
NZ (1) NZ543693A (el)
PE (1) PE20050143A1 (el)
PL (1) PL1633726T3 (el)
PT (2) PT1471057E (el)
RU (1) RU2361865C2 (el)
SI (1) SI1633726T1 (el)
TW (1) TWI353980B (el)
UY (1) UY28286A1 (el)
WO (1) WO2004096777A1 (el)
ZA (1) ZA200508722B (el)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
CA2551110C (en) * 2003-12-23 2016-01-19 Tanox, Inc. Treatment of cancer with novel anti-il 13 monoclonal antibodies
RU2373208C2 (ru) * 2004-01-31 2009-11-20 Актимис Фармасьютикалз, Инк. Производные имидазо[1,2-c]пиримидинилуксусной кислоты
AU2005229356B2 (en) 2004-03-11 2011-06-09 Idorsia Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
SI1817282T1 (sl) 2004-11-23 2011-10-28 Astrazeneca Ab Derivati fenoksiocetne kisline, uporabni za zdravljenje respiratornih bolezni
MX2007012937A (es) 2005-04-21 2008-03-26 Serono Lab Pirazina-sulfonamidas 2,3-sustituidas.
PT1891075E (pt) 2005-05-24 2011-11-10 Merck Serono Sa Derivados espiro tricíclicos como moduladores do crth2
PE20070589A1 (es) * 2005-10-04 2007-06-22 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007039736A1 (en) * 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
EA200802415A1 (ru) * 2006-06-09 2009-06-30 Икос Корпорейшн Замещенные фенилуксусные кислоты в качестве dp-2-антагонистов
JP2010519328A (ja) * 2007-02-26 2010-06-03 ファイザー・プロダクツ・インク H−pgdsの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンd2が媒介する疾患の治療のためのそれらの使用
CN102898380A (zh) 2007-06-21 2013-01-30 艾克提麦斯医药品有限公司 一种crth2 拮抗剂的胺盐
NZ581811A (en) * 2007-06-21 2012-11-30 Actimis Pharmaceuticals Inc Particulates of the CRTH2 antagonist { 4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)-benzyl)pyrimidin-5-yl} acetic acid
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
EP2205569B1 (en) 2007-09-25 2012-02-29 Actimis Pharmaceuticals, Inc., Alkylthio pyrimidines as crth2 antagonists
NZ584351A (en) * 2007-09-25 2012-03-30 Actimis Pharmaceuticals Inc 2-S-benzyl substituted pyrimidines as CRTH2 antagonists
US8067445B2 (en) 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US20110190227A1 (en) 2008-07-03 2011-08-04 Amira Pharmaceuticals, Inc. Antagonists of Prostaglandin D2 Receptors
EP2328876B1 (en) 2008-09-02 2012-11-21 Actimis Pharmaceuticals, Inc., Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
CA2747795A1 (en) 2008-12-25 2010-07-01 Taisho Pharmaceutical Co., Ltd. Isoquinoline derivative
JP2012517405A (ja) * 2009-02-09 2012-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器及び胃腸の疾患の治療のための新規医薬組成物
CA2751260A1 (en) 2009-02-12 2010-08-19 Stefano Crosignani Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Dp2 수용체 길항제의 안과용 약학 조성물
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
JP2013501052A (ja) 2009-08-05 2013-01-10 パンミラ ファーマシューティカルズ,エルエルシー. Dp2アンタゴニストおよびその用途
AU2010324980A1 (en) * 2009-11-24 2012-05-03 Boehringer Ingelheim International Gmbh Process for preparing a polymorph of the choline salt of a pyrimidin-5-yl acetic acid derivative
EA201270653A1 (ru) 2010-01-06 2012-11-30 ПАНМИРА ФАРМАСЬЮТИКАЛС, ЭлЭлСи Антагонист dpи его применение
ES2545865T3 (es) 2010-01-27 2015-09-16 Boehringer Ingelheim International Gmbh Compuestos de pirazol como antagonistas de CRTH2
JPWO2011162274A1 (ja) 2010-06-23 2013-08-22 大正製薬株式会社 イソキノリン誘導体
AU2011275417A1 (en) 2010-07-05 2013-02-21 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
EP2598143A1 (en) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
WO2012013567A1 (en) 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical composition for treatment of respiratory and inflammatory diseases
RU2560414C2 (ru) 2010-10-20 2015-08-20 Вэлспар Сорсинг, Инк. Система покрытия на водной основе с улучшенной адгезией к подложкам с покрытием и подложкам без покрытия, в том числе к коррозийно-стойкой нержавеющей стали
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
TWI527809B (zh) 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為crth2拮抗劑之吡唑化合物
JP5999387B2 (ja) 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Crth2拮抗薬としてのピラゾール化合物
PT2709988T (pt) * 2011-05-16 2017-09-08 Boehringer Ingelheim Int Processo para preparar ácido [4,6-bis-dimetilamino-2-[4-(4-trifluorometilbenzoil-amino)benzil]pirimidin -5-il] acético
CA2859284A1 (en) 2011-12-16 2013-06-20 Atopix Therapeutics Limited Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
US9255090B2 (en) 2011-12-21 2016-02-09 Actelion Pharmaceuticals Ltd. Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
CA2876808A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
US20140148470A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―フェニル―5―ピリミジンカルボキシアミド類及びその合成用中間体
GB9125842D0 (en) * 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
WO2001090074A2 (en) * 2000-05-22 2001-11-29 Leo Pharma A/S BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a)
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (en) 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
NZ581811A (en) 2007-06-21 2012-11-30 Actimis Pharmaceuticals Inc Particulates of the CRTH2 antagonist { 4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)-benzyl)pyrimidin-5-yl} acetic acid
CN102898380A (zh) 2007-06-21 2013-01-30 艾克提麦斯医药品有限公司 一种crth2 拮抗剂的胺盐

Also Published As

Publication number Publication date
MXPA05011399A (es) 2006-05-31
JP2006524645A (ja) 2006-11-02
AU2004233966A1 (en) 2004-11-11
TW200505873A (en) 2005-02-16
AU2004233966B2 (en) 2010-11-11
KR20060089622A (ko) 2006-08-09
MY147984A (en) 2013-02-28
UY28286A1 (es) 2004-11-30
ZA200508722B (en) 2006-12-27
HN2004000129A (es) 2009-05-14
RU2005136655A (ru) 2006-06-10
DE60303238T2 (de) 2006-09-14
NO20055588D0 (no) 2005-11-25
US7812160B2 (en) 2010-10-12
AR043885A1 (es) 2005-08-17
DK1633726T3 (da) 2011-03-28
ES2257616T3 (es) 2006-08-01
EP1633726A1 (en) 2006-03-15
RU2361865C2 (ru) 2009-07-20
ATE316077T1 (de) 2006-02-15
CN101914065A (zh) 2010-12-15
CA2523439A1 (en) 2004-11-11
CN1809539B (zh) 2012-05-09
EP1471057B1 (en) 2006-01-18
JP4671955B2 (ja) 2011-04-20
US20100322980A1 (en) 2010-12-23
KR101110491B1 (ko) 2012-01-31
ES2358424T3 (es) 2011-05-10
SI1633726T1 (sl) 2011-04-29
GT200400079A (es) 2004-11-30
NO20055588L (no) 2006-01-24
TWI353980B (en) 2011-12-11
BRPI0409733A (pt) 2006-05-09
PL1633726T3 (pl) 2011-06-30
US7960393B2 (en) 2011-06-14
CN1809539A (zh) 2006-07-26
DE602004030907D1 (de) 2011-02-17
PT1633726E (pt) 2011-02-22
DOP2004000875A (es) 2004-10-31
JP2011068657A (ja) 2011-04-07
EP1633726B1 (en) 2011-01-05
PT1471057E (pt) 2006-05-31
US20070129355A1 (en) 2007-06-07
WO2004096777A1 (en) 2004-11-11
JP5161290B2 (ja) 2013-03-13
HK1095320A1 (en) 2007-05-04
DK1471057T3 (da) 2006-05-15
DE60303238D1 (de) 2006-04-06
EP1471057A1 (en) 2004-10-27
CA2523439C (en) 2012-06-19
ATE494279T1 (de) 2011-01-15
CL43596B (es) 2005-03-18
NZ543693A (en) 2009-05-31
PE20050143A1 (es) 2005-04-01
IL171566A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
CY1111295T1 (el) Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2
CY1110977T1 (el) Υποκατεστημενα παραγωγα ινδολης για φαρμακευτικη συνθεση για θεραπεια ασθενειων του αναπνευστικου
EA200702614A1 (ru) Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот
CY1113029T1 (el) Παραγωγα αζαδικυκλο [3.1.0] εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
CY1110104T1 (el) Παραγωγα της πιπεραζινης ως αναστολεις ταχυκινινων
CY1119261T1 (el) Παραγωγα θειαζολιου
ECSP056130A (es) Compuestos farmacéuticos novedosos
UY28625A1 (es) Nuevos compuestos farmacéuticos
CY1111469T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ 3-ΦΑΙΝΥΛΘΕΙΟ-1Η-ΙΝΔΟΛΗ-1-ΟΞΙΚΟΥ ΟΞΕΟΣ ΩΣ ΡΥΘΜΙΣΤΕΣ ΤΗΣ ΔΡΑΣΗΣ ΤΟΥ ΥΠΟΔΟΧΕΑ CRTh2
ATE491703T1 (de) Phthalazinonderivate
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
SE0201635D0 (sv) Novel compounds
CY1111425T1 (el) ΠΑΡΑΓΩΓΑ ΤΗΣ ΠΥΡΙΔΟ[2,1-a]-ΙΣΟΚΙΝΟΛΙΝΗΣ ΩΣ DPP-IV ΑΝΑΣΤΟΛΕΙΣ
CY1111671T1 (el) Ετεροκυκλικη ενωση
SE0303180D0 (sv) Novel compounds
EA200801381A1 (ru) Производные пиримидина
UY30842A1 (es) Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
CY1113497T1 (el) Παραγωγα κινολινης ως ενδιαμεσες ενωσεις σε μυκοβακτηριακους αναστολεις
TW200640869A (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
EA200600621A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7